Liu Zhi-Jin, Feng Lin-Sen, Li Feng, Yang Li-Rong, Wang Wan-Qi, He Yuan, Meng Zong-Ting, Wang Yu-Feng
Department of Geriatric Oncology, The Third Affiliated Hospital of Kunming Medical University - Yunnan Cancer Hospital, Kunming, China.
Department of Hematology, The Sixth Affiliated Hospital of Kunming Medical University-Yuxi People's Hospital, Yuxi, China.
Front Oncol. 2023 Jul 18;13:1182821. doi: 10.3389/fonc.2023.1182821. eCollection 2023.
To develop a Thyroid Cancer Self-Perceived Discrimination Scale (TCSPDS) to identify patients at high risk for psychological problems and to test its reliability, validity and acceptability.
Using classical test theory, a total of 176 thyroid cancer patients from November 2021 to October 2022 were recruited to develop the TCSPDS. Item analysis was used to improve the preliminary TCSPDS. Exploratory factor analysis (EFA), confirmatory factor analysis (CFA) and structural equation model (SEM) were used to test the construct validity of the final TCSPDS. Pearson correlation coefficient was used to analyze the validity coefficient between TCSPDS and EORTC QLQ-C30 to test the criterion-related validity (CRV) of the final TCSPDS. The internal consistency coefficient (Cronbach's alpha coefficient), split half reliability (Spearman-Brown coefficient) and test-retest reliability were used to verify the reliability of the final TCSPDS. The questionnaire completion time and effective response rate were used to validate the acceptability of the final TCSPDS.
The TCSPDS consisted of 20 items and was divided into 3 subscales: 8 items for stigma, 6 items for self-deprecation, and 6 items for social avoidance. The TCSPDS had good validity (χ/df=1.971, RMSEA=0.074, GFI=0.921, CFI= 0.930, IFI=0.932, TLI=0.901, Validity coefficient=0.767), reliability (Cronbach's alpha=0.867, Spearman-Brown coefficient=0.828, test-retest reliability coefficient=0.981) and acceptability [average completion time (15.01 ± 1.348 minutes) and an effective response rate of 95.14%]. Patients with higher TCSPDS scores reported a lower quality of life (<0.05).
The TCSPDS could be used for early identification and assessment of the level of self-perceived discrimination in patients with thyroid cancer, which may provide a scientific basis for health education, social support and psychosocial oncology services in the future, especially in Southwest China.
编制甲状腺癌自我感知歧视量表（TCSPDS），以识别有心理问题高风险的患者，并检验其信度、效度和可接受性。
运用经典测验理论，于2021年11月至2022年10月招募了176例甲状腺癌患者来编制TCSPDS。采用项目分析来完善初步的TCSPDS。运用探索性因素分析（EFA）、验证性因素分析（CFA）和结构方程模型（SEM）来检验最终TCSPDS的结构效度。采用Pearson相关系数分析TCSPDS与欧洲癌症研究与治疗组织核心生活质量问卷（EORTC QLQ-C30）之间的效度系数，以检验最终TCSPDS的效标关联效度（CRV）。采用内部一致性系数（Cronbach's alpha系数）、分半信度（Spearman-Brown系数）和重测信度来验证最终TCSPDS的信度。采用问卷完成时间和有效应答率来验证最终TCSPDS的可接受性。
TCSPDS由20个条目组成，分为3个分量表：污名化8个条目、自我贬低6个条目、社交回避6个条目。TCSPDS具有良好的效度（χ/df = 1.971，RMSEA = 0.074，GFI = 0.921，CFI = 0.930，IFI = 0.932，TLI = 0.901，效度系数 = 0.767）、信度（Cronbach's alpha = 0.867，Spearman-Brown系数 = 0.828，重测信度系数 = 0.981）和可接受性[平均完成时间（15.01 ± 1.348分钟），有效应答率为95.14%]。TCSPDS得分较高的患者报告生活质量较低（<0.05）。
TCSPDS可用于早期识别和评估甲状腺癌患者的自我感知歧视水平，这可能为未来的健康教育、社会支持和心理社会肿瘤学服务提供科学依据，尤其是在中国西南部地区。
